These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 23756372)

  • 1. A forensic analysis of drug targets from 2000 through 2012.
    Munos B
    Clin Pharmacol Ther; 2013 Sep; 94(3):407-11. PubMed ID: 23756372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Key factors in the rising cost of new drug discovery and development.
    Dickson M; Gagnon JP
    Nat Rev Drug Discov; 2004 May; 3(5):417-29. PubMed ID: 15136789
    [No Abstract]   [Full Text] [Related]  

  • 3. Reinventing bioinnovation.
    Kaitin KI; Honig PK
    Clin Pharmacol Ther; 2013 Sep; 94(3):279-83. PubMed ID: 23963211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muddied messages about FDA.
    Miller HI
    Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009.
    Kaitin KI; DiMasi JA
    Clin Pharmacol Ther; 2011 Feb; 89(2):183-8. PubMed ID: 21191382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2018 in review: FDA approvals of new molecular entities.
    Kinch MS; Griesenauer RH
    Drug Discov Today; 2019 Sep; 24(9):1710-1714. PubMed ID: 31158510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drug approvals for 2002.
    Frantz S; Smith A
    Nat Rev Drug Discov; 2003 Feb; 2(2):95-6. PubMed ID: 12572538
    [No Abstract]   [Full Text] [Related]  

  • 8. The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    de la Torre BG; Albericio F
    Molecules; 2018 Feb; 23(3):. PubMed ID: 29495494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons from 60 years of pharmaceutical innovation.
    Munos B
    Nat Rev Drug Discov; 2009 Dec; 8(12):959-68. PubMed ID: 19949401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in antimicrobial drug development: implications for the future.
    Spellberg B; Powers JH; Brass EP; Miller LG; Edwards JE
    Clin Infect Dis; 2004 May; 38(9):1279-86. PubMed ID: 15127341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011.
    Lanthier M; Miller KL; Nardinelli C; Woodcock J
    Health Aff (Millwood); 2013 Aug; 32(8):1433-9. PubMed ID: 23918488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An analysis of original research contributions toward FDA-approved drugs.
    Patridge EV; Gareiss PC; Kinch MS; Hoyer DW
    Drug Discov Today; 2015 Oct; 20(10):1182-7. PubMed ID: 26113307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in pharmaceutical targeting of clinical indications: 1930-2013.
    Kinch MS; Merkel J; Umlauf S
    Drug Discov Today; 2014 Nov; 19(11):1682-1685. PubMed ID: 24881779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    de la Torre BG; Albericio F
    Molecules; 2020 Feb; 25(3):. PubMed ID: 32050446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications.
    Shih HP; Zhang X; Aronov AM
    Nat Rev Drug Discov; 2018 Jan; 17(1):19-33. PubMed ID: 29075002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of new companies for drug discovery: origins of a decade of new drugs.
    Kneller R
    Nat Rev Drug Discov; 2010 Nov; 9(11):867-82. PubMed ID: 21031002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The FDA Breakthrough-Drug Designation - Four Years of Experience.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2018 Apr; 378(15):1444-1453. PubMed ID: 29641970
    [No Abstract]   [Full Text] [Related]  

  • 18. The impact of external innovation on new drug approvals: A retrospective analysis.
    Liu X; Thomas CE; Felder CC
    Int J Pharm; 2019 May; 563():273-281. PubMed ID: 30664998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2016 in review: FDA approvals of new molecular entities.
    Griesenauer RH; Kinch MS
    Drug Discov Today; 2017 Nov; 22(11):1593-1597. PubMed ID: 28687460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pipelines turn to biotech.
    Lawrence S
    Nat Biotechnol; 2007 Dec; 25(12):1342. PubMed ID: 18066015
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.